CHO Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of innovative products based on the proprietary glycan engineering technologies. Its products include CHO-H01 & CHO-H02 antibody for cancer; CHO-H03 antibody for autoimmune disease; CHO-A04 antibody for cancer; CHO-S05 dual-effect anti-flu drug; and CHO-V07 glycan-based vaccines & drugs. The company was founded by Kong Ming Lu on March 8, 2013 and is headquartered in Nangang, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company